Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer

[1]  B. Győrffy,et al.  Mapping of Genomic Vulnerabilities in the Post-Translational Ubiquitination, SUMOylation and Neddylation Machinery in Breast Cancer , 2021, Cancers.

[2]  A. Chiang,et al.  UBE2C Drives Human Cervical Cancer Progression and Is Positively Modulated by mTOR , 2020, Biomolecules.

[3]  B. Győrffy,et al.  TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues , 2020, bioRxiv.

[4]  A. Green,et al.  The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer , 2020, Breast Cancer Research and Treatment.

[5]  A. Green,et al.  Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype , 2020, Pathobiology.

[6]  Shen Hu,et al.  UBE2C promotes the progression of head and neck squamous cell carcinoma. , 2019, Biochemical and biophysical research communications.

[7]  A. Green,et al.  Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer , 2019, Breast Cancer Research and Treatment.

[8]  Hongbo Wang,et al.  UBE2C Is Upregulated by Estrogen and Promotes Epithelial–Mesenchymal Transition via p53 in Endometrial Cancer , 2019, Molecular Cancer Research.

[9]  Jun Zhao,et al.  UBE2C overexpression in melanoma and its essential role in G2/M transition , 2019, Journal of Cancer.

[10]  Matteo Cereda,et al.  A Comprehensive Bioinformatics Analysis of UBE2C in Cancers , 2019, International journal of molecular sciences.

[11]  Xiaohong Wang,et al.  UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC , 2019, Theranostics.

[12]  I. Ellis,et al.  The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts , 2019, Modern Pathology.

[13]  W. Sauerbrei,et al.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration , 2018, Journal of the National Cancer Institute.

[14]  G. Ma,et al.  Overexpression of UBE2C correlates with poor prognosis in gastric cancer patients. , 2018, European review for medical and pharmacological sciences.

[15]  A. Jemal,et al.  Breast cancer statistics, 2017, racial disparity in mortality by state , 2017, CA: a cancer journal for clinicians.

[16]  Zhen-bo Feng,et al.  The clinicopathological significance of UBE2C in breast cancer: a study based on immunohistochemistry, microarray and RNA-sequencing data , 2017, Cancer Cell International.

[17]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[18]  I. Ellis,et al.  Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections , 2017, Breast Cancer Research and Treatment.

[19]  Chang-zhi Huang,et al.  Ubiquitin proteasome system research in gastrointestinal cancer. , 2016, World journal of gastrointestinal oncology.

[20]  Steven J. M. Jones,et al.  Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.

[21]  A. Mukherjee,et al.  Molecular Mechanisms Underlying Lymphovascular Invasion in Invasive Breast Cancer , 2015, Pathobiology.

[22]  Tsung-Hsien Chang,et al.  Ubiquitin-Conjugating Enzyme UBE2C Is Highly Expressed in Breast Microcalcification Lesions , 2014, PloS one.

[23]  Toshima Z. Parris,et al.  Additive effect of the AZGP1, PIP, S100A8 and UBE2C molecular biomarkers improves outcome prediction in breast carcinoma , 2014, International journal of cancer.

[24]  R. Kurzrock,et al.  Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  M. Kahn,et al.  β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression. , 2013, Cancer research.

[26]  K. Winzer,et al.  The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions , 2013, PloS one.

[27]  C. Velde,et al.  Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer † , 2013 .

[28]  Hiroko Masuda,et al.  Role of epidermal growth factor receptor in breast cancer , 2012, Breast Cancer Research and Treatment.

[29]  I. Ellis,et al.  The prognostic significance of lymphovascular invasion in invasive breast carcinoma , 2012, Cancer.

[30]  N. Pavlidis,et al.  Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[32]  Hui Zhang,et al.  Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker , 2012, Tumor Biology.

[33]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[34]  H. Nevanlinna,et al.  High cyclin B1 expression is associated with poor survival in breast cancer , 2009, British Journal of Cancer.

[35]  I. Ellis,et al.  The p53 positive Bcl‐2 negative phenotype is an independent marker of prognosis in breast cancer , 2007, International journal of cancer.

[36]  J. Pines.  Mitosis: a matter of getting rid of the right protein at the right time. , 2006, Trends in cell biology.

[37]  G. Ball,et al.  High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.

[38]  S. Pinder,et al.  E‐cadherin expression in invasive non‐lobular carcinoma of the breast and its prognostic significance , 2005, Histopathology.

[39]  L. Porter,et al.  Cyclin B1 and CDK1: nuclear localization and upstream regulators. , 2003, Progress in cell cycle research.

[40]  R. Mayer,et al.  The ubiquitin-proteasome pathway of intracellular proteolysis. , 2002, Essays in biochemistry.

[41]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[42]  T. Kameya,et al.  Involvement of cyclins in cell proliferation and their clinical implications in soft tissue smooth muscle tumors. , 2000, The American journal of pathology.

[43]  P. Nurse.  Universal control mechanism regulating onset of M-phase , 1990, Nature.

[44]  E B Cox,et al.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.